VOR NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Vor Biopharma Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 19.26 USD
6.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 27.2% above the Trend Line and sits at 27.4% of its 52-week range. The latest completed week returned 6.5%, after a 19.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 57/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 46 out of 100
Latest Close 19.26 USD 24 Jul 2026
1W Return 6.5% latest completed week
4W Return 19.6% short-term follow-through
12W Return 39.1% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 10-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • 6 accumulation markers appear in the recent smart-money tape.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 37.96% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.5% Latest completed week; four-week move 19.6%. Indicator stack 60/87 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 37.96% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 57/100 conviction; expected move 22.0%. News sentiment 52/100 41 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 27.2% above the Trend Line and sits at 27.4% of its 52-week range. The latest completed week returned 6.5%, after a 19.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3612-week average 0.17

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.36Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

6 accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 19.6% over four weeks, 39.1% over 12 weeks, and -56.2% over one year. The current trend has remained active for 10 consecutive weeks.

Performance by holding period

1W6.5%
4W19.6%
12W39.1%
26W16.1%
52W-56.2%
Active trend streak10 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.37Latest activity-pressure read.
Pressure change151.6%Four-week change in activity pressure.
Leadership-13.50Latest relative-leadership reading.
RS change64.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength30/100Blend of value, momentum, and quality. Underlying universe rank 71; rank 1 is best.
Value41/100Relative valuation strength. Underlying universe rank 60; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
2.0x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-17.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-38.6%
Net share repurchases relative to market value.
Shareholder yield
-38.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

VOR shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of n/a, expected move of 22.0%, and Sharemaestro trend signal active.

Conviction57/100
Expected move22.0%
Put/call volume
Pressure-100
Speculation20
Volatility96
Trend agreement3
Open options detail
Insider activity10 / 7

10 acquisitions and 7 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 41 relevant articles.

7 positive · 29 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move22.0%Nearest-chain priced movement where available.
52-week drawdown-63.7%Distance below the 52-week high.
13-week volatility11.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+27.9%Week of 3 Jul.
Worst week-21.6%Week of 30 Jan.
Latest week+6.5%Week of 24 Jul.

Shape of recent returns

Strong gains11
Modest gains3
Flat weeks0
Modest losses3
Sharp losses9
Recent vol11.8%13-week weekly-return volatility.
Base vol16.4%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew13.2% / -11.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape42/100

Trend, activity pressure, participation, and risk combine to a 42/100 tape read.

 Indicator analysis65/100

Latest 12-week confirmation: trend 10/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.36; No reversal markers Next-Week ExpectancyNegative 37.96%

Next-week expectancy is negative with a 37.96% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 60 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options37/100

VOR shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of n/a, expected move of 22.0%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 22.0% Sentiment52/100

Weighted news tone is neutral across 41 relevant articles.

Vor Biopharma (VOR) Stock May Already Look Fully Priced On Pipeline Hopes Insiders10 / 7

10 acquisitions and 7 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202619.26 USD6.5%15.15 USD26.11 USD1.37-13.504.2MOn
17 Jul 202618.09 USD-5.5%15.00 USD26.35 USD1.35-22.344.6MOn
10 Jul 202619.14 USD-7.0%14.81 USD26.66 USD1.20-23.588.9MOn
3 Jul 202620.59 USD27.9%14.59 USD26.91 USD0.91-19.199.5MOn
26 Jun 202616.10 USD11.1%14.17 USD27.13 USD0.54-37.6111.8MOn
19 Jun 202614.49 USD0.9%13.91 USD27.43 USD0.43-46.826.6MOn
12 Jun 202614.36 USD9.1%13.68 USD27.89 USD0.47-45.604.1MOn
5 Jun 202613.16 USD-12.1%13.53 USD28.44 USD0.59-48.643.3MOn
29 May 202614.97 USD4.5%13.72 USD29.00 USD0.82-43.912.6MOn
22 May 202614.33 USD-2.1%14.02 USD29.53 USD0.66-44.384.7MOn
15 May 202614.63 USD-13.6%14.45 USD30.05 USD0.52-42.124.9MOff
8 May 202616.94 USD22.3%14.93 USD30.53 USD0.55-32.704.2MOff
1 May 202613.85 USD0.3%15.41 USD30.97 USD0.50-41.393.1MOff
24 Apr 202613.81 USD-16.8%16.19 USD31.39 USD0.71-40.875.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.